CHOSA Oncology AB Logo

CHOSA Oncology AB

Develops diagnostics and therapeutics for platinum-based chemotherapy.

CHOSA | SPGR

Overview

Corporate Details

ISIN(s):
SE0007784319
LEI:
5493002SFL9YXB0A0027
Country:
Sweden
Address:
C/O Medicon Village, C/O Medicon Village, Scheeletorget 1, 223 81 Lund

Description

CHOSA Oncology AB is a biotechnology company focused on advancing precision medicine for platinum-based chemotherapy. The company's strategy integrates diagnostics and therapeutics to personalize patient care. Its primary asset is Platin-DRP®, a patented diagnostic tool that analyzes a tumor's genetic profile to predict its response to cisplatin and carboplatin. This technology aims to improve survival rates and prevent the administration of ineffective, toxic treatments to non-responding patients. Complementing this is LiPlaCis®, a novel drug formulation that delivers cisplatin directly to tumors via a specialized liposome system, designed to enhance efficacy while minimizing side effects. The company's technologies are being validated in various cancers, including lung and breast cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CHOSA Oncology AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CHOSA Oncology AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CHOSA Oncology AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.